NUVATION BIO INC NUVB 深 滬
已收盤 11-06 16:00:00 美东时间
4.16
-0.030
-0.72%
華盛通- 最 高4.329
- 今 開4.21
- 成交量 533.59万股
- 最 低 3.975
- 昨 收 4.19
- 總市值 14.61亿
- 52周最高 9.75
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 3.975
- 委 比 -92.57%
- 總股本 3.51亿
- 歷史最高 15.23
- 量 比 0.87
- 振 幅 8.45%
- 歷史最低 0.95
- 每 手 1
- 風險率 1.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 可口可乐、麦当劳、3M等获多家大行看好；机构上调高通目标价至165美元
今日重点评级关注：Citizens：维持Precigen"跑赢大市"评级，目标价从11美元升至12美元；Leerink Partners：维持Arcus Biosciences"跑赢大市"评级，目标价从46美元升至49美元
11-06 16:15
RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $17.
11-06 03:44
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.
09-30 18:22
Why Is Nuvation Bio Stock Gaining Thursday?
On Thursday, the U.S. Food and Drug Administration (FDA) approved Nuvation Bio Inc.’s (NYSE:NUVB) supplemental New Drug Application (sNDA) regarding its oncology drug IBTROZI (taletrectinib). Following the announcement, the stock gained over 6%. The approval comes four months ahead of the PDUFA date...
09-18 00:46
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroups Among patients who received IBTROZI after prior chemotherapy, response rates remained con...
09-15 20:06
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13
JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating and announces Price Target of $13.
08-18 20:24
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
